Zacks
PODD Stock Benefits From FDA Approval of Omnipod 5's Enhancements
📈
AI Sentiment
Highly Positive
8/10
- Home
- PODD
PODD
Insulet Corporation
as of 12-09-2025 3:43pm EST
$294.62
$1.57
-0.53%
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
Chart Type:
Time Range:
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | ACTON |
| Market Cap: | 22.1B | IPO Year: | 2007 |
| Target Price: | $359.00 | AVG Volume (30 days): | 762.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 19 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 3.45 | EPS Growth: | -39.84 |
| 52 Week Low/High: | $230.05 - $354.88 | Next Earning Date: | 11-06-2025 |
| Revenue: | $2,521,800,000 | Revenue Growth: | 27.11% |
| Revenue Growth (this year): | 32.55% | Revenue Growth (next year): | 20.39% |
AI-Powered PODD Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 71.52%
71.52%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Insulet Corporation (PODD)
STONESIFER TIMOTHY C.
Buy
Director
PODD Dec 5, 2025
Avg Cost/Share
$311.73
Shares
962
Total Value
$299,884.26
Owned After
4,591
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| STONESIFER TIMOTHY C. | PODD | Director | Dec 5, 2025 | Buy | $311.73 | 962 | $299,884.26 | 4,591 |
Latest Insulet Corporation News
PODD Breaking Stock News: Dive into PODD Ticker-Specific Updates for Smart Investing
Simply Wall St.
Assessing Insulet’s Valuation After Omnipod Expansion and Recent Share Price Volatility
âž–
AI Sentiment
Neutral
5/10
StockStory
2 High-Flying Stocks with Impressive Fundamentals and 1 We Turn Down
📊
AI Sentiment
Positive
6/10
MT Newswires
Insulet Wins FDA Clearance for Updated Omnipod 5 Algorithm
âž–
AI Sentiment
Neutral
5/10
Business Wire
Insulet Announces FDA 510(k) Clearance of Omnipod® 5 Algorithm Enhancements that Redefine Insulin Delivery and Simplify the Pod Experience
📈
AI Sentiment
Highly Positive
8/10
Compare PODD vs Leading Stocks
See how PODD stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PODD Insulet Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.